Ipsen: business results up in 2024
(CercleFinance.com) - Ipsen reports a 12.
1% increase in net income for 2024 to E857.8m, or E10.27 per share, and a 0.6-point improvement in its operating margin to 32.6%.
At E3.4bn, the pharmaceutical company's sales were up 9.9% at constant exchange rates (+8.7% on a reported basis), driven by a solid performance in all therapeutic areas, particularly rare diseases (+67.4%).
Ipsen points out that sales of its Somatuline (lanreotide) product rose by 5.6%, while sales of the non-Somatuline portfolio recorded double-digit growth of 12.2%.
A dividend of E1.40 per share, up 16.7%, will be proposed for 2024. For 2025, Ipsen is targeting total sales growth in excess of 5% at constant exchange rates, and an operating margin above 30%.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
1% increase in net income for 2024 to E857.8m, or E10.27 per share, and a 0.6-point improvement in its operating margin to 32.6%.
At E3.4bn, the pharmaceutical company's sales were up 9.9% at constant exchange rates (+8.7% on a reported basis), driven by a solid performance in all therapeutic areas, particularly rare diseases (+67.4%).
Ipsen points out that sales of its Somatuline (lanreotide) product rose by 5.6%, while sales of the non-Somatuline portfolio recorded double-digit growth of 12.2%.
A dividend of E1.40 per share, up 16.7%, will be proposed for 2024. For 2025, Ipsen is targeting total sales growth in excess of 5% at constant exchange rates, and an operating margin above 30%.
Copyright (c) 2025 CercleFinance.com. All rights reserved.